ストックスクリーナーアプリを入手
29.41
6.40%
1.77
アフターアワーズ：
29.75
0.34
+1.16%
前日終値:
$27.64
開ける：
$27.71
24時間の取引高:
594.29K
Relative Volume:
1.18
時価総額：
$1.30B
収益：
-
当期純損益:
$-166.31M
株価収益率:
-6.5939
EPS:
-4.4602
ネットキャッシュフロー:
$-160.59M
1週間 パフォーマンス:
+16.48%
1か月 パフォーマンス:
+23.05%
6か月 パフォーマンス:
+42.91%
1年 パフォーマンス:
+57.86%
1日の値動き範囲:
$27.71
$29.49
1週間の範囲:
$25.17
$29.49
52週間の値動き範囲:
$16.10
$29.49
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Compare AVBP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
29.41 | 1.22B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-12-10 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | 開始されました | Truist | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet - MSN
Are you looking for a top momentum pick? Why ArriVent BioPharma, Inc. (AVBP) is a great choice - MSN
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice - Yahoo Finance
Are medical stocks lagging ArriVent BioPharma, Inc. (AVBP) this year? - MSN
Understanding Momentum Shifts in (AVBP) - Stock Traders Daily
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - Yahoo Finance
Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Surprises Report: How does SAPH compare to its peers2026 Macro Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Arrivent Biopharma stock hits 52-week high at 27.25 USD By Investing.com - Investing.com Australia
Arrivent Biopharma stock hits 52-week high at 27.25 USD - Investing.com
ArriVent BioPharma, Inc. (AVBP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet - Yahoo Finance
Wall Street experts predict that ArriVent BioPharma, Inc. (AVBP) may climb by 72.44%. Check this out before making any investment decisions. - Bitget
ArriVent to present preclinical cancer drug data at AACR 2026 - MSN
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest - Yahoo Finance
AVBP Technical Analysis & Stock Price Forecast - Intellectia AI
Avoiding Lag: Real-Time Signals in (AVBP) Movement - Stock Traders Daily
Clear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
Gains Report: Whats next for ArriVent BioPharma Inc stock2026 Technicals & Weekly Breakout Stock Alerts - baoquankhu1.vn
Aug Highlights: How do insiders feel about ArriVent BioPharma IncAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 8.4%Here's Why - MarketBeat
Aug Mood: Can ArriVent BioPharma Inc maintain sales growth2026 Investor Takeaways & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum Shift - Sahm
RONB Should I Buy - intellectia.ai
BCSM Should I Buy - intellectia.ai
GLND Should I Buy - Intellectia AI
DNMXU Should I Buy - Intellectia AI
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year? - Yahoo Finance
ArriVent BioPharma (NASDAQ:AVBP) Upgraded to Strong-Buy at Truist Financial - MarketBeat
MQY Should I Buy - Intellectia AI
VCX Should I Buy - Intellectia AI
Burkina Faso Integrates National Languages into AI Development Strategy - techafricanews.com
Weekly Investment Analysts’ Ratings Changes for ArriVent BioPharma (AVBP) - Defense World
ArriVent to Present Preclinical Cancer Drug Data at AACR 2026 - mychesco.com
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP) - Seeking Alpha
Discipline and Rules-Based Execution in AVBP Response - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $45.00 at B. Riley Financial - MarketBeat
B. Riley Securities Maintains Buy on ArriVent... - Benzinga
Arrivent Biopharma, Aveanna Healthcare Holdings, EQT - TradingView
Weekly Earnings: Is ArriVent BioPharma Inc subject to activist investor interest2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Is ArriVent BioPharma (AVBP) Offering Value After Recent Share Price Pullback? - Sahm
Is ArriVent BioPharma, Inc. (AVBP) stock outpacing its medical peers this year? - MSN
ArriVent BioPharma Unveils Promising Preclinical Data on Firmonertinib and Dual-Target ADC ARR-002 at 2026 AACR Annual Meeting - Minichart
ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Truist Securities Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 - BioSpace
ArriVent Highlights Next-Generation Oncology Data at AACR 2026 - TipRanks
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - The Manila Times
ArriVent to present preclinical data on firmonertinib and dual-target ADC ARR-002 at AACR 2026 - TradingView
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):